Prognostic value of epidermal growth factor-receptor, T138 (Thbukait et al., 1982; Dolbeare et al., 1983) it is difficult to predict tumour progression precisely: classical clnicopathological prognostic factors are not able to predict which superficial tumours will lead to infiltration and which infiltrating tumours will generate distant metastases. The ability to identify high-risk patients would enable us to choose between conservative and radical treatment at an early stage and to better nvestigate multimodal therapy in advanced diseas. The need for new, independent prognostic markers has led to studies of antibodies for determining bladder tumour immunophenotype.
Using hybridoma technology, several monoclonal antibodies against tumour-associated antgens have been developed (Young et al., 1985) . Experimental data suggest that malignant transformation can be accompanied by modifications of the cell phenotype, e.g. the loss of antgens usually present at the cell surface or the appearance of new antigens. Potential markers inchlde T43 and T138 antigens, which are glycoproteins of respectively M, 85 000 and Mr 25 000, defined by monoclonal antibodies produced with the hybridoma method . T43 and T138 antigens show sgnifintly increased expression in infiltrative tumours and have potential prognostic value: it has been suggsted that T43-and T138-positive bladder tumours have a poorer prognosis and that the expression of T138 antigen is a better single indicator than ploidy (determined by flow cytometry). In low-grade superficial tumours (Fradet et al., 1987) Recently, attention has been drawn to growth factors, since an autocrine loop may be involved in the transformation or progression of human cancer. Epidermal growth factor (EGF) is a 53 amino acid peptide originally isolated (Cohen, 1962) from the submaxillary gland of the male mouse. It is a potent stimulator of growth and division in cells of many different types. It is now clear that EGF belongs to a family of related peptides which are assocated with the malignant phenotype, such as transforming growth factor alpha (TGF-a). The actions of EGF and TGF-a are mediated by binding to a specific membrane receptor which has a close strncturl relationship with the oncogene product of erb-B (Gulfick, 1990) . The intracellular portion of EGFR has an assocated tyrosine kinas domain and three tyrosine residues which are autophosphorylated after binding of EGF and induce signal transmion to the nucleus (King, 1985) . Inceased levels of this receptor have been found in several cancers, including bladder cancer. Previous studies (Neal et al., 1985; Messing et al., 1987) 
Results

Immunohistochemistrv
Immunostaining patterns are reported in Table I. 19A211 antigen was more strongly expressed in superficial tumours (P = 0.05) (Figures 1 and 2) and there was no good correlation with tumour grade. T43 (Figures 3 and 4) (Figure 7) , with no difference according to grade. When it was expressed in normal bladders or superficial tumours, expression was strongest in the basal layer cells (Figure 8 ). EGFR, T138 and T43 expression in bladder cancer V Ravery et al 199 Survival probability Surface antigen phenotypes correlated with the clinical findings at the time of sampling and with outcome. As expected, a low incidence of progression (14.7%, 5/34) was observed in patients with superficial (Ta-TI) tumours, contrasting with a progression rate of 82.6% (19/23) in patients with deeply infiltrating tumours. Tumour stage (P<0.001) and histological grade (0.001 <P<0.01) were significant predictors of outcome for the entire group. Antigen phenotype correlated with clinical progression. Only three markers had significant predictive value for the progression rate using the log-rank test (Figure 9 ): EGFR (P = 0.017), T138 (P = 0.0009) and T43 (P = 0.03 1). The cancer progressed only in 6/25 (24%) patients with EGFR-negative samples, 6/34 (17.6%) with T138-negative samples and 11/35 (31.4%) with T43-negative samples. In contrast, the cancer progressed in 18/32 (56.3%) patients with EGFR-positive samples, 18/23 (78.3%) with T138-positive samples and 13/22 (59.1%) with T43-positive samples. Using the stepwise logistic regression, two factors appear to have a significant and independent prognostic value: stage (P = 0.0001) and T138 expression (P= 0.006).
Discussion
The pattern of 19A21 1, T43 and T1 38 monoclonal antibodies staining in our tumour panel is in accordance with previous descriptions (Fradet, 1987) . 19A211 was detected in approximately 60% of papillary superficial tumours (Ta/Tl) and in situ carcinomas; in deeply infiltrating cancers (T2/T3) antigen expression was only 35% of the tumours. In our study these values were significantly different (respectively 70.6% and 47.8%). Antigens T43 and T138 have been described as cancer progression antigens : T43 expression is limited to metabolically active cells of the proximal kidney tubule and the basal cell layer of pluristratified squamous epithelia. T43 was expressed in 15-20% of superficial bladder tumours and 60% of invasive bladder cancers in a previous study (Fradet et al., 1987) ; in ours, these percentages were respectively 29.4% and 52.2%. T138 has been reported to be expressed in similar proportions on bladder tumours, and our results confirm that it is expressed in 26.5% of superficial and 60.9% of invasive tumours. It is now known that the 25 kDa surface glycoprotein detected by antibody T138 is restricted in normal tissues to endothelial cells of blood and lymph vessels, as confirmed in this study. As a result, it has been speculated that T138 could be involved in the metastatic process.
Independent studies (Berger et al., 1987; Messing, 1990; Neal et al., 1990) have shown that muscle-invasive tumours are more likely than superficial tumours to be EGFR positive when stained immunohistochemically. Our data are in agreement with a statistical significant difference (69.6% vs 47%). The greater expression of EGFR in invasive tumours of the bladder could imply a role for this receptor in bladder tumour invasiveness. The reason for the heterogeneity of receptor distribution and particularly the increased expression from superficial to deep layer urothelial cells in healthy bladders and in superficial tumours is not clear. It could be partly because of the more active division of basal cells in well-differentiated tumours, this difference being suppressed in undifferentiated tumours in which cell-cell cohesions and interactions are looser. Samples which express EGFR are not necessarily dependent on EGF for growth: they may be abnormal and be active whether or not EGF is bound to the receptor.
The prognostic value of DNA analysis of bladder tumours, in addition to clinicopathological parameter, remains controversial. It has been shown (Fradet, 1990 ) that ploidy alone is not an entirely reliable prognostic indicator because a significant proportion of non-progressing tumours were aneuploid, while a few samples from patients with cancer progression were diploid (20%). We found an interesting and significant predictive progression value for T43, T138 and EGFR expression. In agreement with a prognosis study using flow cytometry , we found that T138 was a better prognostic tool than T43. T138 is expressed on epithelial tumoral cells and endothelial cells in stromal tissue. In this evaluation, we considered a tumour to be positive only if the epithelial cells were positive. Expression of T138 on endothelial cells was not taken into account in this analysis. If confirmed, it would suggest that these two tumour-associated antigens may be early indicators of aggressiveness. EGFR is also a preferential tool to predict progression, as shown previously (Neal et al., 1990) . In future, these biological markers should be evaluated for the prediction of other clinical features, such as the recurrence rate of superficial tumours and the response to systemic treatment. Finally, given their prognostic value, these markers could be useful for screening tumours at an early stage when radical treatment is still a valid option. Combined flow cytometry (FCM) analysis of DNA and antigen phenotyping with monoclonal antibodies has shown that expression or non-expression of T43 and T138 increases the prognostic value of progression of ploidy. In our study, the progression rate was profoundly influenced by T138, T43 and EGFR expression using the univariate analysis, but only T138 expression has an independent prognostic value, and this is a new finding. These molecules, and especially T138, appear to be useful markers of tumour aggressiveness, which may influence therapeutic decisions. They should now be studied on a larger panel of tumours and compared with ploidy states. Simple and reproducible tests on a minimal amount of tumour material and, possibly quantitative assay by enzymelinked immunosorbent assay or image analysis would give these markers wide clinical usefulness in the management of bladder cancer.
